Novo Nordisk A/s

Innate Pharma S.a.s.

University of Genoa

Centre National De La Recherche Scientifique

Novo Nordisk-a/s Novo Alle

Innate Pharma

Innate Pharma, S.a.

Novo Norkisk A/s

Universita Di Genova

Peter Andreas Nicolai Reumert Wagtmann

Stefan Zahn

Anders Svensson

Francois Romagne

Ivan Svendsen

Alessandro Moretta

Pascale Andre

Søren Berg Padkær

Mariella Della Chiesa

Laurent Gauthier

Kristian Kjaergaard

Petrus Johannes Louis Spee

Inger Lund Pedersen

Kristian Kjærgaard

Pieter Spee

Joakim Glamann

Birgitte Friedrichsen

Soren Berg Padkjaer

Elisabeth Douglas Galsgaard

Véronique Braud

Birgitte Urso

Rune Viig Overgaard

Lene Hjorth Alifrangis

Matthias Thorolfsson

Michael Wilken

Rozana Sten

Francois Romagné

Laurant Gauthier

Birgitte Ursø

Matthias Thórólfsson

Milchael Wilken

Petrus Johannes Loius Spee

Søren Berg Padkjær

Pieter Johannes Louis Spee

Soren Berg Padkaer

François Romagne

Rozana Svensson

Birgitte UrsØ

Francois RomagnÉ

Søren Berg Padkaer

A novel IgG4 isotype anti-KIR antibody, novel formulations of this and other IgG4 anti-KIR antibodies, and methods of using such formulations are provided. Also described are compositions, formulations, dosages, and administration regimens suitable for NK cell activation and therapeutic applications of anti-KIR antibodies, as well as kits comprising one or more anti-KIR antibodies with instructions for use in treating cancer.

Anti-KIR antibodies, formulations, and uses thereof

The present invention provides isolated anti-human NKG2D monoclonal antibodies useful for therapeutic applications in humans. Typically, the antibodies are fully human or humanized to minimize the risk for immune responses against the antibodies when administered to a patient. Preferred antibodies include human monoclonal antibodies MS and 21F2. As described herein, other antigen-binding molecules such as, e.g., antigen-binding antibody fragments, antibody derivatives, and multi-specific molecules, can be designed or derived from such antibodies.

Antibodies against human NKG2D and uses thereof

Compositions comprising anti-KIR antibodies and one or more secondary anti-cancer agents or anti-viral agents and methods of using such combinations (as combination compositions or in separate administration protocols) in the treatment of cancers (e.g., lung cancer) or viral infection (e.g., HIV or HCV infection) are provided.

Anti-KIR combination treatments and methods

The present invention relates to agents and methods that are capable of augmenting NK-mediated killing of target cells by reducing inhibitory KIR signalling without reducing the binding of KIR to HLA-C. As described herein, transduction of negative signaling via KIR, upon binding of KIR to its HLA class I ligand, can involve a ligand-binding induced, conformational reorientation of the KIR molecules allowing interactions to form between adjacent KIRs in specific domains, leading to accelerated clustering. Methods and agents such as monoclonal antibodies for reducing KIR-mediated inhibition of NK cell cytotoxicity without reducing or blocking HLA-binding by, e.g., reducing or blocking dimerization of KIR, are provided.

KIR-binding agents and methods of use thereof

The present invention relates to monoclonal antibodies that are capable of specifically binding to lectin-like transcript 1 (LLT1), to polynucleotides encoding such antibodies, and to cells that express such antibodies. antibodies of the invention have utility in the treatment of autoimmune diseases and cancer, in which LLT1- and CD161-expressing cells play a role in disease pathogenesis.

LLT-1 antibodies with new functional properties

Described are methods of treating viral disease using compounds that block inhibitory NK cell receptors, thereby reducing their inhibition of NK cell cytotoxicity in killing infected target cells. In one embodiment, the compound is an antibody binding, for example, one or more of the human KIR2DL1, KIR2DL2, and KIR2DL3 receptors. In another embodiment, the method further comprises administering a therapeutic antibody or fusion protein which binds an antigen expressed on cells infected with the virus.

Methods of enhancing antibody-based antiviral therapies by administering KIR2DL-binding antibodies

The present invention provides isolated anti-human NKG2D monoclonal antibodies useful for therapeutic applications in humans. Typically, the antibodies are fully human or humanized to minimize the risk for immune responses against the antibodies when administered to a patient. Preferred antibodies include human monoclonal antibodies MS and 21 F2. As described herein, other antigen-binding molecules such as, e.g., antigen-binding antibody fragments, antibody derivatives, and multi-specific molecules, can be designed or derived from such antibodies.

The present invention relates to monoclonal antibodies that are capable of specifically binding to lectin-like transcript 1 (LLT1), to polynucleotides encoding such antibodies and to cells that express such antibodies. Antibodies of the invention have utility in the treatment of autoimmune diseases and cancer, in which LLT1-and CD161-expressing cells play a role in disease pathogenesis.

Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.

Human anti-KIR antibodies

The present invention relates to a method of producing an antibody that cross-reacts with multiple KIR2DL polypeptides and neutralizes the inhibitory activity of such polypeptides.

Compositions and methods for regulating NK cell activity

Nucleic acids encoding human anti-kir antibodies

Methods of treating viral infections by administering KIR2DL-binding antibodies

Growing community of inventors

Rungsted Kyst, Denmark

Peter Andreas Nicolai Reumert Wagtmann